Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Allay Therapeutics General Information
Phase 2b registration trial of ATX101 is currently enrolling across U.S. clinical sites. Prior dose-ranging Phase 2b trial demonstrated durable treatment effects with ATX101 versus standard-of-care bupivacaine based on pain intensity out to four weeks, with less use of opioids and meaningful improvement in functional activities up to 60 days following surgery[6].
Contact Information
Website
Primary Industry
Biotech
Corporate Office
San Jose, California
United States
United States
Drug Pipeline
ATX101
Phase 2Key Partnerships
Maruishi Pharmaceutical (Japan), Evonik
Allay Therapeutics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Jun 5, 2025 | $57.5M | Completed | Phase 2 |
To view Allay Therapeutics's complete valuation and funding history, request access »